Kornimate/medical-research-clean huggingface dataset:
korean borderline ovarian tumor (kobot) registry

Conditions: Ovarian Neoplasms

Summary: the aim of this study is to collect data on korean patients with borderline ovarian tumors.

the researchers retrospectively collected data on korean patients with borderline ovarian tumors (bots) diagnosed, treated, and followed between november 1994 and february 2015 at institutions where placed in the republic of korea. and the researchers prospectively will collect data on all korean patients with bots at institutions where placed in the republic of korea since march, 2015. if patients agree to participate in this kobot registry, patient's data (such as age, body mass index, preoperative findings, laboratory findings, radiologic findings, operative findings, pathologic findings, postoperative findings) will be collected in a research database. the research database will be updated, every 6 month, to include data on patient's disease outcome and follow-up care. although most data will be collected form the medical record, patient may agin be contacted so that researchers can collection some data if it is not in the medical record.

Eligibility criteria:
inclusion criteria: * patients with borderline ovarian tumors (bots) diagnosed, treated, and followed between november 1994 and february 2015 at institutions where placed in the republic of korea. * all patients undergoing gynecologic surgery for bots at institutions where placed in the republic of korea since march, 2015 exclusion criteria: * patients who did not receive primary treatment or follow-up for at least 6 months at each institution were excluded from analysis
the diurnal and nocturnal effect of pilocarpine on intraocular pressure and ocular perfusion pressure

Conditions: Glaucoma, Open-angle; Hypertension, Ocular

Summary: the aim of this study will be to determine the effects of pilocarpine as an adjunct medication to latanoprost monotherapy at multiple intervals throughout a 24-hour period and compare these effects to latanoprost alone.

this study plans to learn more about the effect of pilocarpine on intraocular pressure and ocular perfusion pressure for a full twenty-four hour period. in this study, the investigators seek to better characterize the knowledge base of the intraocular pressure (iop) lowering effects of pilocarpine in patients with open angle glaucoma or ocular hypertension who are currently taking latanoprost. the goal is to define the potential additive effect of pilocarpine throughout a 24-hour period, not only for iop, but for ocular perfusion pressure (defined as 2/3\[diastolicbp + 1/3(systolicbp - diastolicbp)\] - iop). these data will allow to expand current knowledge of the effects of pilocarpine and help determine if this medication has a useful role as an adjunctive treatment in glaucoma.

Eligibility criteria:
inclusion criteria: * current confirmed diagnosis of: * open angle glaucoma, or * ocular hypertension including pigment dispersion glaucoma, and * pseudoexfoliation glaucoma. * current use of topical latanoprost once a day in both eyes for at least 6 weeks * any race/ethnicity exclusion criteria: * females who are currently pregnant or planning to become pregnant during the study period * diagnosis of any other form of glaucoma other than open-angle * intraocular pressure readings of \<14mmhg in either eye when measured during routine office visit in the past 12 months. * schaffer angle grade \< 2 in either eye by gonioscopy * intraocular surgery within 6 months or laser within 3 months * history of retinal tear or detachment in either eye * active iritis in either eye as determined by most recent eye examination * patients who smoke or have irregular daily sleep patterns * patients who have started or changed glucocorticoids therapy in the last 3 months * patients who are currently using medical or recreational marijuana * any use of a non-fda approved medication for glaucoma in the last 3 months

Keywords: open-angle glaucoma ocular hypertension latanoprost pilocarpine
acute myeloid leukemia registry

Conditions: Acute Myeloid Leukemia

Summary: all acute myeloid leukemia (aml) patients diagnosed after 1 jan 2020 will be included to this study.

this is a non interventional prospective disease registry, 250 prospective patients diagnosed with aml across 20 centers in turkey. participating sites will consist of hematology clinics and routine follow-up procedures will be followed-up. all patients diagnosed after 1 jan 2020 as aml will be included and patients will be enrolled during 24 months of period and will be followed-up 36 months. study will be completed in 60 months.

Eligibility criteria:
inclusion criteria: * diagnosed as aml after 1 jan 2020 * patients signed informed consent form exclusion criteria: * patients under 18 years old
effect of different probiotic strains in hypercholesterolemic patients

Conditions: Hyperlipidemias

Summary: regular probiotic use for 8 weeks was evaluated in individual with mild to moderate hyperlipidemia. current study have been determined the use of different probiotics strains on lipid parameters such as; total cholesterol, hdl cholesterol, ldl cholesterol, triglyceride levels as well as glycemic parameters such as; glucose, insulin, homa-ir levels. also, hs-crp levels were investigated as inflammatory parameter.

in the light of recent studies, it has been shown that probiotics may have positive effects on hyperlipidemia. the aim of this study was to investigate the effect of probiotics mainly on blood lipids as well as homocysteine levels, glycemic control parameters and hs-crp levels a randomized, double-blind placebo-controlled study was completed with a total of 51 individuals who have diagnosed with hyperlipidemia. participants were randomly assigned into 3 groups according to the probiotic type they would consume, groups were as follows; lactobacillus (probiotic group i) (n=18), lactobacillus and bifidobacterium (probiotic group ii) (n=17) and placebo group (n= 16). they were all requested to have placebo or probiotic capsules every day for 8 weeks. total cholesterol, hdl cholesterol, ldl cholesterol, triglyceride levels were investigated as lipid metabolism parameters while fasting blood glucose, insulin, homa-ir levels were investigated as glycemic parameters. also, hs-crp levels were investigated as inflammatory parameter.

Eligibility criteria:
inclusion criteria: • had a repeated total cholesterol level ≥200 mg/dl prior to allocate to the study group and to declined conventional lipid lowering medical treatment exclusion criteria: * those with any chronic conditions other than hypercholesterolemia, * individuals with inherited lipid metabolic disorders, * individuals with chronic gastrointestinal disease, * individuals with immunodeficiency, * individuals with malignancy, * individuals with mental disabilities, * patients currently using any lipid lowering drugs, or an alternative treatment to lower blood cholesterol (such as probiotics) and individuals who have used antibiotics in the previous three months prior to study and * pregnant or lactating women were excluded from the study.

Keywords: serum lipids hyperlipidemia probiotics
study of safety and immunogenicity of fluzone® in healthy children

Conditions: Influenza

Summary: to describe the safety of the 2004-2005 pediatric formulation of the inactivated, split-virion influenza vaccine fluzone®, given in the two-dose schedule in accordance with the package insert, in children aged ≥ 6 months to \< 36 months. to describe the immunogenicity of the 2004-2005 inactivated, split-virion influenza vaccine fluzone®, administered in a two-dose schedule in accordance with the package insert, in children aged ≥ 6 months to \< 36 months

to provide the centers for biologic evaluation and research (cber) with sera collected from healthy children receiving the 2004-2005 formulation of the inactivated, split-virion influenza vaccine fluzone® for further study by the food and drug administration (fda), centers for disease control and prevention (cdc), and the world health organization (who).

Eligibility criteria:
inclusion criteria : * participant is aged ≥ 6 months to \< 36 months. * participant is considered to be in good health on the basis of reported medical history and limited physical examination. * participant is available for the duration of the study. * parent/guardian is willing and able to provide informed consent. * parent/guardian is willing and able to meet protocol requirements. exclusion criteria : * reported allergy to egg proteins, chicken proteins, or any other constituent of the vaccine. * previous history of influenza vaccination or documented history of influenza infection. * an acute illness with or without fever (temperature \> 100.4 °f rectal) in the 72 hours preceding enrollment in the trial (defer enrollment). * clinically significant findings in vital signs or review of systems (investigator judgment; defer or exclude). * participation in any other clinical trial within 30 days prior to enrollment up to termination of the subject's participation in the study. * known or suspected impairment of immunologic function, or receipt of immunosuppressive therapy or immunoglobulin since birth. * personal or immediate family history of congenital immune deficiency. * developmental delay, neurologic disorder, or seizure disorder. * chronic medical, congenital, or developmental disorder. * known human immunodeficiency virus (hiv)-positive mother. * prior history of guillain-barré syndrome. * any condition which, in the opinion of the investigator, would pose a health risk to the subject or interfere with the evaluation of the vaccine. * any vaccination in the 14 days preceding enrollment in the study or scheduled between visit 1 and visit 3.

Keywords: influenza fluzone® vaccine infants toddlers
clinical and genetic findings in patients with prpf31-associated retinitis pigmentosa

Conditions: Retinitis Pigmentosa

Summary: retrospective chart review study to elucidate the genotype and phenotype of patients with prpf31-associated retinitis pigmentosa and asymptomatic carriers of the respective variant(s)


Eligibility criteria:
inclusion criteria: * genetically confirmed prpf31-associated inherited retinal dystrophy or asymptomatic carrier of the respective variant(s) exclusion criteria: * none

Keywords: retinitis pigmentosa prpf31 inherited retinal dystrophy carrier
telephone intervention for caregivers of persons with traumatic brain injury

Conditions: Brain Injuries

Summary: this study seeks to determine if problem-based telephone counseling improves quality of life and emotional well-being for caregivers of persons with moderate to severe traumatic brain injury (tbi).

caregivers and patients with tbi are recruited from the acute medical and inpatient rehabilitation units at harborview medical center and the university of washington medical center in seattle, wa. after informed consent is obtained, information is gathered from the caregiver about his/her living situation, support systems, and the nature of the caregiving relationship. additional information is gathered from the person with tbi about how he/she is doing cognitively, socially, and emotionally. prior to discharge home, caregivers are randomly selected to receive either standard care (typical support and/or resources) or standard care plus problem-based telephone counseling. the telephone follow-up group receives a telephone call from a caregiver support specialist at 2, 4, 6, 8, 10, 12, 14, and 16 weeks after discharge of the patient with tbi home with the option of two additional calls. during those calls, the caregiver support specialist provides training on problem-solving skills along with education on topics of interest to caregivers of persons with tbi. an outcome assessment is done at 6 months and 1 year after discharge home.

Eligibility criteria:
inclusion criteria: * family member or other person having a long-term relationship (at least one year) with person with tbi admitted to hospital and discharged home from acute care, inpatient rehabilitation, and/or skilled nursing facility within 7 months of date of injury. * sufficient english to permit communication without an interpreter. exclusion criteria: * lack of a telephone. * lack of a permanent home address.

Keywords: brain injuries, traumatic caregivers
theragun vs dry needling on neck pain, range of motion and disability among heavy weightlifters

Conditions: Dry Needling; Neck Pain; Range of Motion; Weight Lifting

Summary: the study is randomized and single-blinded. ethical approval is taken from ethical committee of riphah international university, lahore. participants who meet the inclusion criteria will be enrolled and allocated in group a \& b through sealed envelope method by non-probability convenient random sampling technique. subjects in group a will receive theragun technique. group b will receive dry needling technique.

the objective of the study is to determine the comparative effects of theragun and dry needling on neck pain, range of motion and disability among heavy weightlifters. the study is randomized and single-blinded. ethical approval is taken from ethical committee of riphah international university, lahore. participants who meet the inclusion criteria will be enrolled and allocated in group a \& b through sealed envelope method by non-probability convenient random sampling technique. subjects in group a will receive theragun technique. group b will receive dry needling technique. neck disability index (ndi), universal goniometer, numeric pain rating scale (nprs) will be used to assess at the baseline and after the completion of treatment at 6 weeks. the data will be analyzed by spss, version 25. statistical significance is p=0.05.

Eligibility criteria:
inclusion criteria: * •male athlete, * 20 -35 years of age, * weight lifting from 1 -2 years, * cervical flexion-rotation test positive exclusion criteria: * • cerebrovascular diseases, * migraine, * cervicogenic headache, * musculoskeletal, cervical spondylosis, cervical spondylolisthesis, * cervical post-operative, * traumatic events in the past three months, * presence of a physical or mental illness

Keywords: theragun dry needling neck pain range of motion disability heavy weightlifters
changes in seroprevalence and wellness over time in healthcare workers (conserve-hcw)

Conditions: COVID-19 Infection

Summary: the investigators propose a multi-center, observational, longitudinal, cohort study of the serology and wellness of hcws over a year of the covid-19 pandemic.

all consenting participants will undergo survey assessment and diagnostic testing with the abbott architect sars-cov-2 igg assay (igg) every three months for a one year period. clinical outcomes and related data capture will be performed at this same interval.

Eligibility criteria:
inclusion criteria: 1. age greater than or equal to 18 years; and 2. be an active member of the commonspirit health workforce or medical staff during the covid-19 pandemic and at the time of enrollment; and 3. have access to the internet; and 4. the ability to provide informed consent. exclusion criteria: 1. subjects that lack the ability for longitudinal follow-up; and/or 2. subjects that do not meet the above inclusion criteria. -

Keywords: serology wellness sars-cov-2 igg seroprevalence healthcare workers
pilot study comparing diagnostic imaging versus tomosynthesis in detection of hip, wrist or tibia injury

Conditions: Wrist Injury; Tibial Fracture; Hip Injury

Summary: to acquire and build a library of image sets to determine if fuji's tomo imaging device can replace or compliment current imaging standards to assess patients with hip, wrist or tibia injuries.

subjects presenting with a wrist injury, tibial fracture, or hip injury that require protocol defined standard imaging will have an x-ray, ct scan (or mri per site preference) and tomo completed. images will be assessed to determine if tomo is appropriate to supplement or replace the need for the other standard images.

Eligibility criteria:
inclusion criteria: * physician request to have diagnostic imaging for condition areas exclusion criteria: * under 18 * pregnancy * insufficient anatomical coverage or potential image problems

Keywords: tomosynthesis
identification of novel markers of human lung disease

Conditions: Lung Diseases, Interstitial

Summary: the purpose of this study is to investigate new therapies for advanced lung disease.

this research study is being conducted to learn about the progression and cause of lung disease. by agreeing to be a part of this study, you will allow the lung tissue which would normally have been discarded after your procedure, to be used for research purposes to allow us to understand more about your condition which may potentially lead to novel treatments and therapeutics. for this study, the investigators will isolate specific cells from the lung tissue and measure cellular, molecular and genetic mechanisms responsible for regulating lung disease. no other type of research will be performed on these samples nor will the samples be given to other investigators for unrelated research.

Eligibility criteria:
inclusion criteria: * any one on lung transplant list exclusion criteria: * hiv positive
microbiome in immunotherapy naïve nsclc patients receiving pd-1/l1 blockade (mip_nsclc)

Conditions: NSCLC Stage IV; NSCLC, Recurrent

Summary: this phase iv study is hoping to determine if examining the microbiome in non-small cell lung cancer, immunotherapy naive participants can predict the effectiveness of immunotherapy treatment as well as determine ahead of time adverse events and their severity. in addition, the investigator will look into microbiome changing modifiers.


Eligibility criteria:
inclusion criteria: * must have tumor tissue biopsy-proven to be nsclc * must have a target lesion to evaluate treatment response * immunotherapy naïve metastatic/advanced/recurrent nsclc patients * will receive single agent anti-pd-1/pd-l1 therapy (e.g. pembrolizumab, nivolumab, atezolizumab, avelumab or durvalumab, etc.). patients can be on other interventional trial if they will be receiving single agent anti-pd-1/pd-l1 exclusion criteria: * prior treatment with any forms of cancer immunotherapy * not competent to make medical decision, noncommunicative or noncompliant per treating physician's judgement * not english-speaking * patients that are pregnant * prisoners * students and employees * psychiatric illness/social situations that would limit compliance with study requirements

Keywords: advanced nsclc metastatic nsclc recurrent nsclc
a study to evaluate the effectiveness and safety of rxi 109 on the outcome of scar revision surgery in healthy adults

Conditions: Hypertrophic Scar

Summary: the purpose of this study is to determine the effectiveness of rxi-109 in reducing the recurrence of hypertrophic scar formation following elective revision of a pre-existing hypertrophic abdominal scar.


Eligibility criteria:
inclusion criteria: * adults, 21-55 years of age in general good health * previous partial hysterectomy, cesarean section or abdominoplasty surgery resulting in a transverse hypertrophic scar of ≥ 11 cm in length * scar to be revised must have been present for \> 9 months exclusion criteria: * use of tobacco or nicotine-containing products * pregnant or lactating * post-menopausal or full hysterectomy

Keywords: hypertrophic scar cicatrix scar prevention scar revision
a study of detection of paroxysmal events utilizing computer vision and machine learning - nelli

Conditions: Epilepsy

Summary: nelli is a video-based non-eeg physiological seizure monitoring system. this study is a blinded comparison of nelli's identified events to gold-standard video eeg review in at-rest pediatric subjects with suspected motor seizures.

automated analysis of video recordings to detect seizures, assisted by modern methods of machine learning, holds great promise to address this issue. increased computational power has made it possible to implement complex image recognition tasks and machine learning in everyday use. nelli® software is designed to use computer vision and machine learning-based algorithms to automatically detect seizure events. this study will provide evidence that nelli software can identify seizure events and deliver objective data to clinicians for evaluation of seizure management. this study is being conducted to validate the nelli software's ability to identify periods of audio /video data that contain recordings of patients experiencing seizures (or seizure-like events) during periods of rest. the software's performance will be compared to the gold standard, expert review of video eeg data. nelli software will review the audio and video data and independently identify events with positive motor manifestations. the outcomes of event identification will be compared between epileptologists and the nelli software. for each category of event captured the positive percent agreement will be calculated using the exact binomial method. the primary endpoint of this study is to demonstrate that nelli is able to identify seizures that have a positive motor component with a sensitivity of \>70% (lower 95% ci) and with a false discovery rate (fdr) comparable to similar devices on the market.

Eligibility criteria:
inclusion criteria: * subject shall sign informed consent. * subject is between 6 and 21 years. * subjects shall be undergoing video-eeg monitoring for routine clinical purposes. * subjects shall have a suspected history of motor seizures. * subject shall be able to understand and sign written informed consent or have a legally authorized representative (lar) who can do so, prior to the performance of any study assessments. exclusion criteria: * none identified.
united kingdom user evaluation, minimed paradigm® x54 system

Conditions: Diabetes Mellitus, Type 1

Summary: the user evaluation is to assess user acceptance and the quality of training materials for the minimed paradigm® x54 system (x54 system) in preparation for commercial distribution of the new system.


Eligibility criteria:
inclusion criteria: * are current 512/712, 515/715 or 522/722 minimed paradigm insulin pump users, with or without cgm experience, and have at least three months experience with any one of these devices; * have signed an informed consent and are willing to comply with the user evaluation procedures; * have an hba1c value less than 9.0% recorded at the time of their last test (if no hba1c value is available within three months of enrollment, an hba1c should be performed prior to entry to verify inclusion criteria); * are willing to use the bolus wizard feature; * agree to complete a diary for the duration of the study; * agree to complete a questionnaire at the conclusion of the study; * have been diagnosed with type 1 diabetes mellitus by appropriate fasting or non fasting lab blood glucose values, c-peptide, insulin antibodies, prior documented dka or good clinical picture at least six months prior to study start; * are 18 - 65 years of age; * have access to the internet and agree to upload the device per protocol exclusion criteria: * is pregnant or planning to become pregnant during the course of the user evaluation. pregnancy screening will be completed during the routine office visit prior to evaluation for the study. if a woman becomes pregnant during participation, she will be withdrawn; * suffers from a chronic debilitating condition; * has serious or unstable medical or psychological conditions (e.g., eating disorders, clinical depression, anxiety disorder) which, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study; * has impaired vision or hearing problems that could compromise the handling of the device; * has a history of tape allergies or skin conditions that could interfere with continued use of the system; * has the potential for lack of compliance or any other issue, in the opinion of the investigator, that may preclude the subject from satisfactory participation in the study; * has travel plans which would make it difficult for the subject to attend on-site study visits as scheduled; * is currently participating in an investigational study (drug or device).